Carlos Manchado Perdiguero, PhD, PLD by IESE, MBA by ESADE. BSc in Biochemistry, Molecular Biology and Biology. He has been working in Roche Diagnostics since 1998. In his early career he held several position with business development and commercial responsibilities. In 2008 he was appointed as Marketing Director for Applied Sciences and member of the Innovation Committee of Roche Diagnostics Spain . As of 2013 he has been developing his work as Director for Innovation and Projects Roche Diagnostics Spain, where he has developed several R+D project, has faces the issues that prevent R+D outcomes to reach the market and has taken advantage of its experience in knowledge management.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
This project has received funding from the European Union´s Horizon 2020 research and innovation programme under grant agreement No 686009